Neurochemical and behavioral characterization of neuronal glutamate transporter EAAT3 heterozygous mice

Luis F. González1,2†, Francisca Henríquez-Belmar2,3†, Claudia Delgado-Acevedo2,3, Marisol Cisternas-Olmedo2,3, Gloria Arriagada5, Ramón Sotomayor-Zárate1, Dennis L. Murphy6 and Pablo R. Moya2,3,4*

Abstract

Background: Obsessive–compulsive disorder (OCD) is a severe neuropsychiatric condition affecting 1–3% of the worldwide population. OCD has a strong genetic component, and the SLC1A1 gene that encodes neuronal glutamate transporter EAAT3 is a strong candidate for this disorder. To evaluate the impact of reduced EAAT3 expression in vivo, we studied male EAAT3 heterozygous and wild-type littermate mice using a battery of behavioral paradigms relevant to anxiety (open field test, elevated plus maze) and compulsivity (marble burying), as well as locomotor activity induced by amphetamine. Using high-performance liquid chromatography, we also determined tissue neurotransmitter levels in cortex, striatum and thalamus—brain areas that are relevant to OCD.

Results: Compared to wild-type littermates, EAAT3 heterozygous male mice have unaltered baseline anxiety-like, compulsive-like behavior and locomotor activity. Administration of acute amphetamine (5 mg/kg intraperitoneally) increased locomotion with no differences across genotypes. Tissue levels of glutamate, GABA, dopamine and serotonin did not vary between EAAT3 heterozygous and wild-type mice.

Conclusions: Our results indicate that reduced EAAT3 expression does not impact neurotransmitter content in the corticostriatal circuit nor alter anxiety or compulsive-like behaviors.

Keywords: EAAT3, SLC1A1, Neuronal glutamate transporter, Obsessive–compulsive disorder

Background

Obsessive–compulsive disorder (OCD) is a persistent, disabling neuropsychiatric condition affecting 1–3% of the worldwide population. OCD is characterized by persistent intrusive thoughts (obsessions), repetitive ritualistic behaviors (compulsions) and excessive anxiety [1]. Family, twin and case–control studies have shown that genetic factors play a major role in OCD (for a review, see [2]).

Altered glutamatergic neurotransmission has been postulated in the etiology of OCD. The glutamatergic hypothesis has accumulated evidence from neuroimaging studies [3, 4], animal models with altered glutamatergic neurotransmission exhibiting compulsive-like behaviors [5–7] and reports of beneficial effects of anti-glutamatergic agents on treatment-resistant OCD [8]. Genetic linkage and association studies have implicated glutamate system genes in OCD; among them, the most consistent candidate gene in OCD is SLC1A1 (solute carrier, family 1, member 1) gene [1, 9–15]. SLC1A1 encodes for the neuronal excitatory amino acid transporter EAAT3, with reported roles in controlling glutamate spillover which affects extrasynaptic NMDA and metabotropic glutamate receptors activity [16, 17].

Mice lacking EAAT3 (KO) were first reported 20 years ago; the original report showed that EAAT3 KO mice have reduced locomotor activity, but no neurological or cognitive impairments [18]. Given its role in cysteine
uptake, EAAT3 KO mice also have neuronal glutathione depletion and greatly enhanced susceptibility to oxidative damage [18, 19]. No comprehensive behavioral assessment, in particular OCD-related behaviors was available until a very recent report showing that EAAT3 KO mice have unaltered baseline anxiety-like or compulsive-like behaviors, and reduced sensitivity to behavioral effects induced by amphetamine or SKF-38393, a dopamine D1 receptor agonist [20].

Animal models with diminished, rather than absent gene expression are of clinical relevance, because they might better reflect the impact of human polymorphisms affecting protein levels, where complete loss of expression is very rare [21]. Therefore, to assess the role of reduced EAAT3 expression, we evaluated the neurochemical and behavioral alterations in EAAT3 heterozygous (HET) mice.

**Methods**

**Animals**

Male mice carrying a targeted knockout Slc1a1 gene were generated at the NIMH Transgenic Core Facility using a construct obtained from Knockout Mouse Project Consortium (KOMP) (clone ID: PG00093 Z_1_807) under a standard protocol. Briefly, linearized construct was electroporated in embryonic stem (ES) cells; after selection screening, targeted ES cells were injected into C57BL/6N blastocysts and chimeric mice were bred with C57BL/6J to test for germ line transmission and to establish the targeted lines. The official designation of these mice is B6-Slc1a1tm1a(KOMP)Wtsi. By the time of experimental procedures, 10 crosses onto C57BL/6J have been made. Three to five months old EAAT3 HET and wild-type (WT) littermates were used in all experiments. Mice were housed in groups of 3–5 per cage on a 12-h light:12-h dark cycle (lights on at 07:00) with food and water ad libitum in a facility approved by the Institutional Animal Welfare Committee. Efforts were made to minimize the number of animals used and their suffering.

Genotyping was performed using genomic DNA from 0.5 cm tail biopsies. DNA extraction was performed by standard procedures. LoxP primers flanking downstream LoxP site generate at 210 bp band in knockout allele, and 185 bp in wild-type allele: LoxP-For (5'-ACCAATTTCCACACCCTCCTCAGC-3'); LoxP-Rev (5'-GATTTCGTTTCTACCTCGGGCCTA-3'). 1a1-En2 primers targeting the initial 3′ portion of the cassette interrupting transcription generate a 500 bp in the KO allele and no band in the WT allele: 1a1En2-forward (5'-TGGCTCGGGTTTCTCCTAGCTGGT-3'); 1a1-En2-Rev (5'-GAAAGATTCCAGCAA and GCTGACGGTGAGTAGCACAA for Slc1a1; TGTCTATGCGCACAACACT and TCCTCAACACTGCAGTCACG for Slc1a2; GGATGGAAAAGATTCCAGCAA and GCTGACGGTGAGTAGCACAA for Slc1a3; AAAACTTGGCTTTCCCTGTT and TCTGGCCTGTATCAGACACTTC for Hprt1). Real-time PCR was performed with using Brilliant III UltraFast SYBR Green qRT-PCR Master Mix (Santa Clara, CA, USA) and integrity confirmed by non-denaturant horizontal electrophoresis in agarose during 1 h at 120 V. Reverse transcription was performed using 10 ng of total RNA using the Takara Prime script Reagent kit containing genomic DNA elimination step (Clontech, Mountain View, CA, USA). Slc1a1 (EAAT3), Slc1a2 (GLT-1a, the major isoform in brain) and Slc1a3 (GLAST) mRNA levels were measured with respect to the housekeeping gene Hypoxanthine-guanine phosphoribosyltransferase 1 (Hprt1) mRNA using the following primers: GCTACATGCCGATGGCATT and TACCCAAGGCAAAGC GGAA for Slc1a1; TGTCTATGCGCACAACACT and TCCTCAACACTGCAGTCACG for Slc1a2; GGATGGAAAAGATTCCAGCAA and GCTGACGGTGAGTAGCACAA for Slc1a3; AAAACTTGGCTTTCCCTGTT and TCTGGCCTGTATCAGACACTTC for Hprt1.

**EAAT3 Western Blot**

EAAT3 HET and WT mice were killed by cervical dislocation; brains were removed immediately and striatum was dissected on a glass-plate set in ice, and stored at −80 °C until use. Total RNA was extracted from homogenized striata by sonication and using RNAeasy Mini Kit (Qia-gen, Carlsbad, CA, USA), and eluted with RNase-free water. RNA was quantified using a nanospectrophotometer (Nanodrop ND-1000, Thermo Scientific, Waltham, MA, USA) and integrity confirmed by non-denaturant horizontal electrophoresis in agarose during 1 h at 120 V. Reverse transcription was performed using 10 ng of total RNA using the Takara Prime script Reagent kit containing genomic DNA elimination step (Clontech, Mountain View, CA, USA). Slc1a1 (EAAT3), Slc1a2 (GLT-1a, the major isoform in brain) and Slc1a3 (GLAST) mRNA levels were measured with respect to the housekeeping gene Hypoxanthine-guanine phosphoribosyltransferase 1 (Hprt1) mRNA using the following primers: GCTACATGCCGATGGCATT and TACCCAAGGCAAAGCGGAA for Slc1a1; TGTCTATGCGCACAACACT and TCCTCAACACTGCAGTCACG for Slc1a2; GGATGGAAAAGATTCCAGCAA and GCTGACGGTGAGTAGCACAA for Slc1a3; AAAACTTGGCTTTCCCTGTT and TCTGGCCTGTATCAGACACTTC for Hprt1. Real-time PCR was performed with using Brilliant III UltraFast SYBR Green qRT-PCR Master Mix (Santa Clara, CA, USA) in a 10 µl reaction volume with primers at 0.2 µM final concentration, using a CFX96 Connect System (Bio-Rad, Hercules, CA, USA). Amplification protocol consisted in 40 cycles as follows: 10 s of denaturation at 95 °C; 45 s of annealing at 58 °C; 15 s of elongation at 72 °C. All reactions were performed in triplicate; expression changes were analyzed as previously described [22].
at 70 °C for 8 min. 30 µg protein were loaded in a polyacrylamide/SDS 8% gel and separated by electrophoresis in running buffer 1× (Tris 2.5 mM, glycine 19.2 mM, SDS 0.01%) by 90 min at 100 V, and then transferred to a nitrocellulose membrane for 90 min at 450 mA in transfer buffer (Tris 2.5 mM, glycine 19.2 mM, SDS 0.01, 20% methanol); transfer was verified using Ponceau red staining. Membranes were washed in TBS-Tween (T-TBS) 1× for 5 min, and then blocked using 5% skim milk solution in PBS for 1 h. Primary monoclonal antibody anti-EAAT3 (AB124802, Abcam, Cambridge, UK) was dissolved in blocking solution and incubated overnight at 4 °C. Next day, membranes were washed three times with T-TBS 0.1% for 5 min. Secondary antibody goat antirabbit (HRP) (ab205718, Abcam) was incubated for 1 h; membranes were then washed three times with T-TBS. Membranes were loaded with Pierce ECL chemiluminescent substrate (ThermoFisher Scientific, Waltham, MA, USA) for 1 min and revealed for 12 min. Beta-actin antibody (ab8227, Abcam) was used as normalizer. Images were analyzed by ImageJ software (NIH, Bethesda, MD, USA) as described previously [22].

Behavioral analyses

Mice in their home cages were acclimated to the behavioral room at least 1 h before analyses. Tests were performed once per day and performed sequentially: Open field, elevated plus maze, marble burying and locomotor activity. All experiments were performed in dim light set at 20 lux; 12–13 mice per group were used.

Open field test: each animal was individually placed in a Plexiglass box (40 × 40 × 35 cm) and allowed to freely explore for 5 min. Behavior including time and frequency in center (20 × 20 cm) were recorded and analyzed using Noldus Ethovision XT (Noldus Information Technology, Leesburg, VA, USA) as previously described [23].

Elevated plus maze test: after acclimation, each mouse was placed in an elevated plus maze (30 cm arm, 46 cm height closed arms) and allowed to freely explore for 5 min. Time and number of entrances to closed and open arms were recorded and analyzed using Ethovision XT.

Marble burying test: after acclimation, mice were individually placed in a clean home cage containing 4–5 cm bedding material; 15 dark glass marbles (1.5 cm diameter) were placed in a 3 × 5 distribution across the surface. After 15 min, mice were removed and the number of marbles buried at least 2/3 of its surface was recorded by an experimenter blind to the animal genotype.

Locomotor activity: baseline horizontal activity was monitored over 30 min in the open field area. Mice received then an intraperitoneal (i.p.) saline injection and were monitored for another 30 min. Next, a single dose of amphetamine (5 mg/kg, i.p.) was administered and activity was recorded for additional 60 min. Videos were analyzed using Noldus Ethovision XT.

Analysis of brain region neurotransmitter and metabolites

In a separate cohort, EAAT3 HET and WT mice were killed by cervical dislocation. Brains were removed immediately and dissected on a glass-plate set in ice, weighed in an analytical balance and stored at −80 °C until use, as previously described [24]. Samples were homogenized according to a protocol modified from Cruz et al. [25]. Briefly, each brain tissue was collected in 400 µL of 0.2 M perchloric acid and then homogenized in a sonicator. The homogenate was centrifuged at 12,000×g for 15 min at 4 °C (model Z233MK-2, Hermle LaborTechnik GmbH, Wehingen, Germany) and the resultant supernatant was filtered (0.2 µm HPLC Syringe Filters disposable filter PTFE, model EW-32816-26, Cole-Parmer Instrument Company, USA). The filtered supernatants were injected into a HPLC coupled to electrochemical detection (for determination of DA, DOPAC, 5-HT and 5-HIAA contents) and fluorometric detection (GLU and GABA).

DA, 5-HT, DOPAC and 5-HIAA quantifications: experimental conditions were as described previously [25–27]. Ten microliters of each cleaned supernatant was injected to the HPLC system with the following setting: A isocratic pump, (model PU-2080 Plus, Jasco Co. Ltd., Tokyo, Japan), a Unijet microbore column (MF-8912, BAS, West Lafayette, IN, USA) and an electrochemical detector (set at 650 mV, 0.5 nA; model LC-4C, BAS, West Lafayette, IN, USA). The mobile phase, containing 0.1 M NaH2PO4, 1.0 mM 1-octanesulfonic acid, 0.27 mM EDTA and 4.0% (v/v) CH3CN (pH adjusted to 2.6) was pumped at a flow rate of 0.1 mL/min. DA, DOPAC, 5-HT and 5-HIAA levels were assessed by comparing the respective peak area and elution time of the sample with a reference standard and the quantification was performed using a calibration curve for each neurotransmitter (Program ChromPass, Jasco Co. Ltd., Tokyo, Japan).

GLU and GABA quantifications: experimental conditions were as described previously [28, 29]. Briefly, 20 µL of each cleaned supernatant was mixed with 4 µL of borate buffer (pH 10.8), and then the mixture was derivatized by adding 4 µL of fluorogenic reagent (20 mg of orthophthaldehyde and 10 µL of β-mercaptoethanol in 5 mL of ethanol). At 90 s after pre-column derivatization, samples were injected into an HPLC system with the following configuration: an isocratic pump (Jasco Co. Ltd.), a C-18 reverse phase column (Kromasil; Eka Chemicals, Bohus, Sweden), and a fluorescence detector configured for an excitation wavelength of 340 nm and an emission wavelength of 450 nm (Jasco Co. Ltd.). A mobile phase containing 0.1 M NaH2PO4 and 14.5% (v/v) CH3CN (pH 26, Cole-Parmer Instrument Company, USA). The mobile phase, containing 0.1 M NaH2PO4, 1.0 mM 1-octanesulfonic acid, 0.27 mM EDTA and 4.0% (v/v) CH3CN (pH adjusted to 2.6) was pumped at a flow rate of 0.1 mL/min. DA, DOPAC, 5-HT and 5-HIAA levels were assessed by comparing the respective peak area and elution time of the sample with a reference standard and the quantification was performed using a calibration curve for each neurotransmitter (Program ChromPass, Jasco Co. Ltd., Tokyo, Japan).

GLU and GABA quantifications: experimental conditions were as described previously [28, 29]. Briefly, 20 µL of each cleaned supernatant was mixed with 4 µL of borate buffer (pH 10.8), and then the mixture was derivatized by adding 4 µL of fluorogenic reagent (20 mg of orthophthaldehyde and 10 µL of β-mercaptoethanol in 5 mL of ethanol). At 90 s after pre-column derivatization, samples were injected into an HPLC system with the following configuration: an isocratic pump (Jasco Co. Ltd.), a C-18 reverse phase column (Kromasil; Eka Chemicals, Bohus, Sweden), and a fluorescence detector configured for an excitation wavelength of 340 nm and an emission wavelength of 450 nm (Jasco Co. Ltd.). A mobile phase containing 0.1 M NaH2PO4 and 14.5% (v/v) CH3CN (pH
was pumped for 4 min. The flow rate of the mobile phase was set at 1.0 mL/min.

**Statistical analyses**

For each experiment, data were analyzed using t-tests or two-way (genotype x drug condition) analyses of variance. Significant interactions were followed by post-hoc comparisons between genotypes or between drug conditions using t-test or Tukey HSD pairwise comparisons. Significance was set on $P < 0.05$. Data are presented as mean ± SEM.

**Results**

We first measured EAAT3 protein in striatal protein preparations from EAAT3 HET and WT littermates. As shown in Fig. 1a, EAAT3 HET mice showed 46% reduction in protein levels compared to WT ($P < 0.0076, n = 4$ mice per group). mRNA levels were also evaluated for Slc1a1 (EAAT3) and other glutamate transporters such as Slc1a2 (GLT1) and Slc1a3 (GLAST). As shown in Fig. 1b, qPCR measurements indicate a downregulation near to a half of Slc1a1 in the EAAT3 HET group compared to expression levels in WT group ($0.0553 ± 0.0743$). Slc1a2 and Slc1a3 mRNA expression values in EAAT3 HET group were not statistically different compared to WT control group ($1.039 ± 0.0994$ and $1.158 ± 0.1010$, respectively, N.S.). Uncropped blot is available in Additional file 1, as well as representative control blot assessing EAAT3 expression in different tissues from WT mice.

Then, we evaluated if reduced EAAT3 expression in EAAT3 HET mice might impact anxiety-like behavior by using the open field test and the elevated plus maze, two well-established behavioral paradigms. No differences were found in the open field test between EAAT3 HET and WT littermates in time spent in center (Fig. 2a; $26.3 ± 3.3$ vs $23.6 ± 2.7$ s, respectively, N.S.; data expressed as mean ± SEM) or in the number of visits to center area (Fig. 2b; $18.7 ± 3.1$ vs $12.7 ± 1.4$, respectively, N.S.). Similarly, as shown in Fig. 2c, we found no differences in the elevated plus maze in EAAT3 HET mice compared to WT littermates in time spent in open arms ($113.4 ± 23.4$ vs $121.0 ± 15.7$ s, respectively, N.S.) or in the number of entries to open arms (Fig. 2d; $15.3 ± 1.0$ vs $16.0 ± 2.1$, respectively, N.S.).

Next, as a proxy of compulsive behavior, we used the marble burying test. As depicted in Fig. 2e, no differences were found between EAAT3 HET mice compared to WT littermates. The numbers of buried marbles were as follows: EAAT3 HET male $= 8.0 ± 1.1$; WT $= 7.5 ± 0.6$, N.S.

![Fig. 1 Reduced EAAT3 expression in EAAT3 heterozygous mice compared to wild-type littermates. a Representative Western Blot showing reduced EAAT3 protein expression in HET mice (H lanes) compared to WT mice (W lanes). b Graph bar of blot quantification; unpaired t-test $P = 0.0076$, $n = 4$ per group. c Real time qPCR detected significantly reduced EAAT3 and unaltered GLT-1 and GLAST mRNA levels in EAAT3 HET mice compared to WT littermates. Unpaired t-test with Welch’s correction (against WT mRNA levels): EAAT3 $P = 0.0025$; GLT-1 $P = 0.9467$, N.S.; GLAST $P = 0.3980$, N.S. $n = 4$ samples per group, each sample run in triplicate. ** indicates $P<0.01$]
Since EAAT3 has been shown to regulate dopaminergic neuron activity, we evaluated if EAAT3 HET mice would have affected sensitivity to amphetamine-induced hyperlocomotion. Figure 3 shows that baseline horizontal locomotor activity was unaltered in EAAT3 HET mice compared to WT littermates over a 30 min observation period. No changes were found upon saline administration. Then, a single dose of amphetamine (5 mg/kg i.p.) was administered; increased locomotion was observed in both groups, being unaffected by genotype (ANOVA drug x genotype N.S., $P = 0.4087$; drug effect $F(1,16); P < 0.0001$).

![Fig. 2](image-url)

**Fig. 2** No differences in anxiety-like or compulsive-like behaviors between EAAT3 heterozygous mice and wild-type littermates. 

| Time spent in center of open field arena; unpaired t-test $P = 0.5272$, N.S. |
| Number of entries to the center of arena (counts); unpaired t-test $P = 0.1154$, N.S. |
| Time spent in open arms of the elevated plus maze; unpaired t-test $P = 0.7840$, N.S. |
| Number of entries (counts) to open arms; unpaired t-test $P = 0.7599$, N.S. |
| Number of buried marbles; unpaired t-test $P = 0.6929$. Data represent the mean ± SEM, 12–13 animals per group |
From a separate cohort of animals, we measured neurotransmitter alterations in prefrontal cortex, striatum and thalamus, areas belonging to the cortical-striatal-thalamic-cortical loop that has been postulated to be altered in OCD [17]. As shown in Table 1, we found no changes in glutamate or GABA tissue content in any of the tested regions; monoamines and their metabolites were also unaltered.

**Discussion**

EAAT3 plays multiple roles in regulating neuronal function that might be relevant for OCD. It is prominently expressed in the cortical-striatal-thalamic-cortical circuit implicated in OCD [30]. EAAT3 is expressed in glutamatergic, GABAergic and dopaminergic neurons [31]. It has been shown that EAAT3 can regulate glutamate clearance, synaptic plasticity and glutamate spillover in excitatory synapses [32, 33]. Our results show that EAAT3 HET mice are unaffected at baseline behavioral levels in anxiety-like or compulsive-like behavior. Tissue content analyses showed no significant changes in glutamate, GABA or monoamine neurotransmitter levels, in any of the evaluated brain regions comprising the CSTC circuit that is dysregulated in OCD. The lack of impact of reduced EAAT3 levels (and plausibly its function) might indicate that protein expression from a single allele copy would suffice to account for EAAT3 activity, without altering the parameters determined here, i.e. tissue neurotransmitter system, anxiety-like and compulsive-like behavior, and amphetamine-induced locomotion. Alternatively, this could be due to compensatory upregulation of other glutamate transporters such as GLT1 and GLAST. We found that Slc1a2 (GLT-1) and Slc1a3 (GLAST) mRNA levels did not significantly vary between EAAT3 HET and WT mice; this is in agreement with previous findings showing that EAAT3 full deletion did not upregulate other glutamate transporters in EAAT3 KO mice [18]. We cannot rule out, however, that significant protein changes might occur for these two glutamate transporters in EAAT3 KO mice; this is in agreement with previous findings showing that EAAT3 full deletion did not upregulate other glutamate transporters in EAAT3 KO mice [18]. We cannot rule out, however, that significant protein changes might occur for these two glutamate transporters in EAAT3 KO mice; this is in agreement with previous findings showing that EAAT3 full deletion did not upregulate other glutamate transporters in EAAT3 KO mice [18]. We cannot rule out, however, that significant protein changes might occur for these two glutamate transporters in EAAT3 KO mice; this is in agreement with previous findings showing that EAAT3 full deletion did not upregulate other glutamate transporters in EAAT3 KO mice [18].

![Fig. 3](image1.png)  
**Fig. 3** No changes in baseline or amphetamine-induced locomotor activity in EAAT heterozygous mice compared to wild-type littermates.  
(a) Locomotor activity baseline and induced by a single dose of amphetamine 5 mg/kg (i.p.).  
(b) Cumulative locomotor activity.  
Two-way ANOVA (genotype x drug) interaction P = 0.4087, N.S. Data represent the mean ± SEM, 6–7 animals per group.

When expressed in GABAergic neurons, EAAT3 provides the precursor for the synthesis of GABA [32]. In this regard, we found no alterations in GABA levels in striatum, region containing a high number of GABAergic medium spiny neurons, suggesting that partial deletion of EAAT3 did not impact tissue levels of this neurotransmitter. However, we cannot rule out that alterations in EAAT3 expression might impact the strength of GABAergic neurotransmission; such possibility needs to be tested thoroughly using approaches like in vivo microdialysis or electrophysiological recordings.
The majority of glutamate is cleared from extracellular space by glial Slc1a2/GLT-1 and Slc1a3/GLAST; it has been estimated that over 80% of glutamate uptake is due to the activity of these transporters [30]. Thus, unaffected glutamate tissue levels were indeed expected since the contribution of EAAT3 to the overall glutamate clearance is minimal.

EAAT3 is expressed in dopaminergic neurons from mesolimbic and nigrostriatal pathways [30, 36]. Recently, Zike and colleagues showed that EAAT3 KO mice have reduced sensitivity to amphetamine effect on locomotor activity [20]. In this regard, we found no significant alterations in amphetamine-induced locomotor activity in EAAT3 HET mice. Correspondingly, levels of DA and DOPAC, its metabolite, were unaltered in the brain regions tested in this report, although we did not measure midbrain areas such as ventral tegmental area or substantia nigra.

Early reports showed EAAT3 KO mice exhibit several neuronal defects largely attributed to oxidative stress due to impaired glutathione synthesis but no OCD-related behaviors [18, 19]. Human SLC1A1 homozygous loss-of-function mutations are extremely rare in humans, and cause the renal condition dicarboxylic aminoaciduria [37] which is also present in EAAT3 KO mice [18]. Rather, common polymorphisms can affect gene expression in less dramatic ways than the loss-of-function represented in a knockout mouse model. As such, we aimed to characterize an intermediate reduction of EAAT3 expression, which could be relevant to the study of neurobiological basis of this disorder [21].

SLC1A1 is one of the most consistently associated genes in OCD. The majority of findings cluster in the 3’ region, and in particular most evidence points to the rs301430C allele [1, 6, 15]. Both in cell assays and post-mortem brain tissue, this allele is associated with increased SLC1A1 expression, suggesting that increased, rather than decreased expression contributes to OCD susceptibility [1, 35]. Therefore, the lack of significant changes in EAAT3 HET mice showed here is consistent with this notion; overexpression EAAT3 experiments are needed to test this hypothesis.

Conclusions
Our results indicate that a Slc1a1 heterozygosis in mice does not alter anxiety- or compulsive-like behaviors evaluated in this work, nor tissue neurotransmitter levels in the cortex, striatum and thalamus, comprising the brain circuit proposed to be altered in OCD. Our data are in line with a recent report [20] finding that EAAT3 KO mice have unaltered spontaneous OCD relevant behaviors.

Additional file

Additional file 1. Uncropped blots for EAAT3 protein determinations.

Table 1 Neurotransmitter tissue contents in EAAT3 HET and WT littermates determined by HPLC coupled to electrochemical (monoamines) and fluorometric (aminoacids) detection

| Slc1a1 genotype | Glutamate (pg/mg tissue) | GABA (ng/mg tissue) | 5-HT (pg/mg tissue) | 5-HIAA (pg/mg tissue) | Dopamine (pg/mg tissue) | DOPAC (pg/mg tissue) |
|-----------------|--------------------------|---------------------|-------------------|----------------------|------------------------|---------------------|
| Prefrontal cortex |                          |                     |                   |                      |                        |                     |
| WT              | 73.1 ± 9.0               | 4605 ± 714.8        | 525.4 ± 30.5      | 5813 ± 45.3          | 35.2 ± 7.7             | N.D                 |
| HET             | 67.7 ± 5.9               | 4923 ± 338          | 466.4 ± 37.2      | 5204 ± 33.0          | 55 ± 12.9              | N.D                 |
| t-test          | NS                       | NS                  | NS                | NS                   | NS                     | NS                  |
| Striatum        |                          |                     |                   |                      |                        |                     |
| WT              | 100.9 ± 10.0             | 6973 ± 463.3        | 473.9 ± 51.5      | 6676 ± 76.8          | 10,631 ± 1147          | 2126 ± 370.6        |
| HET             | 90.1 ± 11.4              | 7658 ± 1372         | 512.8 ± 51.8      | 792.9 ± 72.3         | 9593 ± 1296            | 1818 ± 174.8        |
| t-test          | NS                       | NS                  | NS                | NS                   | NS                     | NS                  |
| Thalamus        |                          |                     |                   |                      |                        |                     |
| WT              | 67.4 ± 7.6               | 13,449 ± 1714       | 720.9 ± 64.5      | 2078 ± 117.8         | 2279 ± 27.2            | 55.3 ± 9.4          |
| HET             | 49.6 ± 9.1               | 11,785 ± 1965       | 618.5 ± 113.4     | 1821 ± 201.3         | 183.1 ± 22.2           | 72.2 ± 11.7         |
| t-test          | NS                       | NS                  | NS                | NS                   | NS                     | NS                  |

Please see “Methods” section for further details. Data are expressed as mean ± SEM.
Authors’ contributions
PRM, DLM and RSZ designed the study. LFG, CDA, FHB and MCO collected the data. LFG, GA, PRM and RSZ carried out the statistical analyses. LFG, GA, PRM and RSZ prepared the figures. All authors wrote the manuscript. All authors read and approved the final manuscript.

Author details
1 Laboratorio de Neuroquímica y Neurofarmacología, Centro de Neurobiología y Plasticidad Cerebral, Instituto de Fisiología, Facultad de Ciencias, Universidad de Valparaíso, Valparaíso, Chile. 2 Laboratorio de Neurogenética, Centro de Neurobiología y Plasticidad Cerebral, Instituto de Fisiología, Facultad de Ciencias, Universidad de Valparaíso, Valparaíso, Chile. 3 Núcleo Milenio Nu-MIND, Biology of Neuropsychiatric Disorders, Valparaíso, Chile. 4 Centro Interdisciplinario de Neurociencias de Valparaíso CINV, Valparaíso, Chile. 5 Departamento de Ciencias Biológicas, Facultad de Ciencias Biológicas, Universidad Andrés Bello, Viña del Mar, Chile. 6 Laboratory of Clinical Science, National Institute of Mental Health, NIH, Bethesda, MD 20892, USA.

Acknowledgements
Not applicable.

Competing interests
The authors declare that they have no competing interests.

Availability of data and materials
The datasets from current study are available from the corresponding author on reasonable request.

Consent for publication
Not applicable.

Ethics approval
All experimental procedures were approved by the Animal Ethics Committee (Protocol BEA-024-2013, Universidad de Valparaíso) and adhered to the guidelines of the American Association for Accreditation of Laboratory Animal Care and National Institutes of Health. Efforts were made to minimize the number of animals used and their suffering.

Funding
This work was mainly supported by FONDECYT Grant 1141272 (PRM), the Intramural Research Program from the National Institute of Mental Health, NIH, Bethesda, USA (DLM); Millennium Nucleus NUMIND (NCI 30011) from the Millennium Scientific Initiative of the Ministry of Economy, Development and Tourism, Chile (PRM and GA), and FONDECYT Grant 11600398 (RSZ). Funding Agencies had no role in the study design, data collection/interpretation or writing of this manuscript.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Received: 7 June 2017 Accepted: 11 September 2017
Published online: 19 September 2017

References
1. Wendland JR, Moya PR, Timpano KR, Anavitarte AP, Kruse MR, Wheaton MG, Ren-Patterson RF, Murphy DL. A haplotype containing quantitative trait loci for SLCA1A1 gene expression and its association with obsessive-compulsive disorder. Arch General Psychiatry. 2009;66(4):408–16.
2. Murphy DL, Moya PR, Wendland JR, Timpano KR. Genetic contributions to obsessive-compulsive disorder (OCD) and OCD-related disorders. In: Nurnberger J, Berrettini W, editors. Principles of psychiatric genetics. Cambridge: Cambridge University Press; 2012. p. 121 –33.
3. Rosenberg DR, Keshavan MS, Bennett Research Award AE. Toward a neurodevelopmental model of obsessive–compulsive disorder. Biol Psychiatry. 1998;43(9):623–40.
4. Rosenberg DR, MacMaster FP, Keshavan MS, Fitzgerald KD, Stewart CM, Moore GJ. Decrease in caudate glutamate concentrations in pediatric obsessive-compulsive disorder patients taking paroxetine. Am J Acad Child Adolesc Psychiatry. 2000;39(9):1096–103.
5. Nordstöm EJ, Burton FH. A transigenic model of comorbid Tourette’s syndrome and obsessive-compulsive disorder circuitry. Mol Psychiatry. 2002;7(6):617–25.
6. Welch JM, Lu J, Rodriguez RM, Trotta NC, Peja C, Ding JD, et al. Cortico-striatal synaptic defects and OCD-like behaviours in Sappap3-mutant mice. Nature. 2007;448:894–900.
7. Shmelkov SV, Hormige A, Jing D, Proenca CC, Bath KG, Milde T, et al. Slt1kr’s deficiency impairs corticostriatal circuitry and leads to obsessive-compulsive-like behaviors in mice. Nat Med. 2010;16:598–602.
8. Pittenger C, Kristal JH, Coric V. Glutamate-modulating drugs as novel pharmacotherapeutic agents in the treatment of obsessive-compulsive disorder. NeuroRx. 2006;3(1):69–81.
9. Hanna GL, Veenstra-VanderWeele J, Cox NJ, Boehnke M, Himle JA, Curtis GC, Leventhal BL, Cook EH Jr, Hanna GL. Association testing of the positional and functional candidate gene SLCA1/A1/EAAC1 in early-onset obsessive compulsive disorder. Arch General Psychiatry. 2006;63(7):769–76.
10. Willour VL, Yao Shugart Y, Samuels J, Grados M, Cullen B, Bienvenu OJ III, Wang Y, Liang KY, Valle D, Hoehn-Saric R, Riddle M, Nestadt G. Replication study supports evidence for linkage to 9p24 in obsessive-compulsive disorder. Am J Hum Genet. 2004;75(3):508–13.
11. Arnold PD, Sicard T, Burroughs E, Richter MA, Kennedy JL. Glutamate transporter gene SLCA1A1 associated with obsessive-compulsive disorder. Arch General Psychiatry. 2006;63(7):778–85.
12. Dickel DE, Veenstra-VanderWeele J, Cox NJ, Wu X, Fischer DJ, Van Etten-Lee M, Himle JA, Leventhal BL, Cook EH Jr, Hanna GL. Association testing of the positional and functional candidate gene SLCA1/A1/EAAC1 in early-onset obsessive compulsive disorder. Arch General Psychiatry. 2006;63(7):778–85.
13. Stewart SE, Fagerness JA, Platko J, Smoller JW, Scharf JM, Illmann C, Jenike E, Chabane N, Leboyer M, Delorme R, Jenike MA, Pauls DL. Association of the SLCA1A1 glutamate transporter gene and obsessive-compulsive disorder. Am J Med Genet B Neuropsychiatr Genet. 2007;144B(8):1027–33.
14. Shugart YY, Wang Y, Samuels JF, Grados MA, Greenberg BD, Knowles JA, McCracken JT, Rauch SL, Murphy DL, Rasmussen SA, Cullen B, Hoehn-Saric R, Pinto A, Fyer AJ, Pacentini J, Pauls DL, Bienvenu OJ, Riddle MA, Liang KY, Nestadt G A family-based association study of the glutamate transporter gene SLCA1 in obsessive-compulsive disorder in 378 families. Am J Med Genet B Neuropsychiatr Genet. 2009;150B:886–92.
15. Stewart SE, Mayerfeld C, Arnold PO, Crane JR, O’Dushlaine C, Fagerness JA, Yu D, Scharf JM, Chan E, Kaisarn F, Moya PR, Wendland JR, Delorme R, Richter MA, Kennedy JL, Veenstra-Vanderweele J, Samuels J, Greenberg BD, McCracken JT, Knowles JA, Fyer AJ, Rauch SL, Riddle MA, Grados MA, Bienvenu OJ, Cullen B, Wang Y, Shugart YY, Pacentini J, Rasmussen S, Nestadt G, Murphy DL, Jenike MA, Cook EH, Pauls DL, Hanna GL, Mathews CA. Meta-analysis of association between obsessive-compulsive disorder and the 3′ region of neuronal glutamate transporter gene SLCA1A1. Am J Med Genet B Neuropsychiatr Genet. 2013;162B(4):367–79.
16. Scrimin A, Tian H, Diamond JS. Neuronal transporters regulate glutamate clearance, NMDA receptor activation, and synaptic plasticity in the hippocampus. J Neurosci. 2009;29:14581–95.
17. Wu K, Hanna GL, Rosenberg DR, Arnold PD. The role of glutamate signaling in the pathogenesis and treatment of obsessive–compulsive disorder. Pharmacol Biochem Behav. 2012;100:726–35.
18. Peghini P, Janzen J, Stoffel W. Glutamate transporter EAAC1-deficient mice develop dicarboxylic aminoaciduria and behavioral abnormalities but no neurodegeneration. EMBO J. 1997;16:3882–32.
19. Aoyama K, Suh SW, Hamby AM, Liu J, Chan WY, Chen Y, Swanson RA. Neuronal glutathione deficiency and age-dependent neurodegeneration in the EAAC1 deficient mouse. Nat Neurosci. 2006;9:119–26.
20. Zike ID, Chohan MO, Kapelson JM, Krasnov EN, Flicker D, Nautiyal KM, et al. OCD candidate gene SLCA1/A1/EAAT3 impacts basal ganglia-mediated activity and stereotypic behavior. Proc Natl Acad Sci USA. 2017;114(22):5719–24.
21. Kaluwef AV, Ren-Patterson RF, Murphy DL. The developing use of heterozygous mutant mouse models in brain monoamine transporter research. Trends Pharmacol Sci. 2007;28(3):122–7.
22. Moya PR, Wendland JR, Salemme J, Fried RL, Murphy DL. miR-15a and miR-16 regulate serotonin transporter expression in human placental and rat brain raphe cells. Int J Neuropsychopharmacol. 2013;16:621–9.

23. Moya PR, Fox MA, Jensen CL, Laporte JL, French HT, Wendland JR, Murphy DL. Altered S-HT2C receptor agonist-induced responses and S-HT2C receptor RNA editing in the amygdala of serotonin transporter knockout mice. BMC Pharmacol. 2011;11:3.

24. Fox MA, Panessiti MG, Moya PR, Tolliver TJ, Chen K, Shih JC, Murphy DL. Mutations in monoamine oxidase (MAO) genes in mice lead to hypersensitivity to serotonin-enhancing drugs: implications for drug side effects in humans. Pharmacogenomics J. 2012;13:551–7.

25. Cruz G, Riquelme R, Espinosa P, Iara P, Dagnino-Subiobre A, Renard GM, Sotomayor-Zárate R. Neonatal exposure to estradiol valerate increases dopamine content in nigrostriatal pathway during adulthood in the rat. Horm Metab Res. 2014;46(5):322–7.

26. Sotomayor-Zárate R, Abarca J, Araya KA, Renard GM, Andrés ME, Gysling K. Exposure to repeated immobilization stress inhibits cocaine-induced increase in dopamine extracellular levels in the rat ventral tegmental area. Pharmacol Res. 2015;101:116–23.

27. Espinosa P, Silva RA, Sanguinetti NK, Venegas FC, Riquelme R, González LF, Cruz G, Renard GM, Moya PR, Sotomayor-Zárate R. Programming of dopaminergic neurons by neonatal sex hormone exposure: effects on dopamine content and tyrosine hydroxylase expression in adult male rats. Neural Plast. 2016;2016:4569785.

28. Ferrada C, Sotomayor-Zárate R, Abacar J, Gysling K. The activation of metabotropic glutamate 5 receptors in the rat ventral tegmental area increases dopamine extracellular levels. NeuroReport. 2017;28(1):28–34.

29. Sotomayor-Zárate R, Araya KA, Pereira P, Blanco E, Quiróz G, Pozo S, Carrero P, Andrés ME, Forray M, Gysling K. Activation of GABA-B receptors induced by systemic amphetamine abolishes dopamine release in the rat lateral septum. J Neurochem. 2010;114(6):1678–86.

30. Kanai Y, Hediger MA. The glutamate/neural amino acid transporter family SLC1: molecular, physiological and pharmacological aspects. Pflugers Arch. 2004;447:469–79.

31. Holmseth S, Dehnes Y, Huang YH, Follin-Arbelet VV, Grutte NJ, Mylonakou MN, Plachez C, Zhou Y, Fumess DN, Bergles DE, Lehve KP, Danbolt NC. The density of EAAC1 (EAAT3) glutamate transporters expressed by neurons in the mammalian CNS. J Neurosci. 2012;32:6000–13.

32. Diamond JS. Neuronal glutamate transporters limit activation of NMDA receptors by neurotransmitter spillover on CA1 pyramidal cells. J Neurosci. 2001;21:8328–38.

33. Sepkuty JP, Cohen AS, Eccles C, Rafiq A, Behar K, Ganel R, Coulter DA, Rothstein JD. A neuronal glutamate transporter contributes to neurotransmitter GABA synthesis and epilepsy. J Neurosci. 2002;22:6372–9.

34. Aida T, Yoshida J, Nomura M, Tanimura A, Ino Y, Soma M, Bai N, Ito Y, Cui W, Aizawa H, Yanagisawa M, Nagai T, Takata N, Tanaka KF, Takayanagi R, Kano M, Gotz M, Hirase H, Tanaka K. Astroglial glutamate transporter deficiency increases synaptic excitability and leads to pathological repetitive behaviors in mice. Neuropsychopharmacology. 2015;40:1569–79.

35. Jarzylo LA, Man HY. Parasympathetic neuronal glutamate transporter function to AMPA receptor synaptic distribution and stability. J Neurosci. 2012;32:2552–63.

36. Underhill SM, Wheeler DS, Liu M, Watts SD, Ingram SL, Amara SG. Amphetamine modulates excitatory neurotransmission through endocytosis of the glutamate transporter EAAT3 in dopamine neurons. Neuron. 2014;83(2):404–16.

37. Bailey CG, Ryan RM, Thoeng AD, Ng C, King K, Vanslambrouck JM, Auray-Blais C, Vandenbarg RJ, Broer S, Rasko JE. Loss-of-function mutations in the glutamate transporter SLC1A1 cause human dicarboxylic aminoaciduria. J Clin Investig. 2011;121:446–53.